FX.co ★ Ocuphire Announces Commercial Launch Of Ryzumvi In U.S. By Its Partner Viatris

On Monday, Ocuphire Pharma, Inc. unleashed in the market their new product titled Ryzumvi. This pharmaceutical ophthalmic solution, with a concentration of 0.75% phentolamine, has been launched across the United States with the help of their partner company, Viatris Inc.

Served as a topical eye drop, Ryzumvi is free of anti-microbial preservatives. It is primarily used to trigger pharmacologically-induced mydriasis, a condition which is typically stimulated by adrenergic agonists or parasympatholytic agents.

Ocuphire and Viatris are bound by a worldwide license agreement, which puts them in a position to co-develop and commercialize Ryzumvi. As stated in the agreement, Ocuphire is eligible to receive regulatory milestones and royalties in conjunction with the commercial performance of Ryzumvi.